Capella-Peris, Carlos http://orcid.org/0000-0003-2520-0650
Cosgrove, Mary M. http://orcid.org/0000-0002-6133-6574
Chrismer, Irene C. http://orcid.org/0000-0002-4240-8165
Emile-Backer, Magalie
Razaqyar, M. Sonia http://orcid.org/0000-0002-8168-0321
Elliott, Jeffrey S.
Kuo, Anna
Wakim, Paul G. http://orcid.org/0000-0002-5951-0983
Meilleur, Katherine G. http://orcid.org/0000-0001-5686-5423
Funding for this research was provided by:
Bench to Bedside Award (10-2013/Office of Rare Disease/NINR)
National Institute of Nursing Research (Intramural Program)
National Institute of Neurological Disorders and Stroke (Intramural Program)
NIH Clinical Center (Intramural Program)
Article History
Accepted: 11 January 2020
First Online: 10 February 2020
Change Date: 1 April 2020
Change Type: Correction
Change Details: The article Mixed methods analysis of Health-Related Quality of Life in ambulant individuals affected with <Emphasis Type="Italic">RYR1</Emphasis>-related myopathies pre-post-<Emphasis Type="Italic">N</Emphasis>-acetylcysteine therapy, written by Carlos Capella-Peris, Mary M. Cosgrove, Irene C. Chrismer, Magalie Emile-Backer, M. Sonia Razaqyar, Jefrey S. Elliott, Anna Kuo, Paul G. Wakim, Katherine G. Meilleur, was originally published electronically on the publisher’s internet portal (<ExternalRef><RefSource>https://doi.org/10.1007/s11136-020-02428-2</RefSource><RefTarget Address="10.1007/s11136-020-02428-2" TargetType="DOI"/></ExternalRef>) on 10 February 2020 with open access. With the author(s)’ decision to step back from Open Choice, the copyright of the article changed on 1 April 2020 to © Springer Nature Switzerland AG, 2020 and the article is forthwith distributed under the terms of copyright.
Change Details: The original article has been corrected.
Compliance with ethical standards
:
: Dr. Carlos Capella-Peris, Ms. Mary M. Cosgrove, Ms. Irene C. Chrismer, Dr. Magalie Emile-Backer, Ms. M. Sonia Razaqyar, Mr. Jeffrey S. Elliott, Ms. Anna Kuo, and Dr. Paul G. Wakim have no conflicts of interest. Dr. Katherine G. Meilleur has received support from the RYR-1 Foundation, and an NIH Clinical Center Bench to Bedside Award (10-2013/Office of Rare Disease/NINR).